Celldex Therapeutics Competitors and Similar CompaniesClear all
Celldex Therapeutics's competitors and similar companies include Deciphera Pharmaceuticals, Marker Therapeutics, Celling Biosciences and UCB.
 Celldex Therapeutics Celldex Therapeutics (formerly Avant Immunotherapeutics) is a biopharmaceutical company that specializes in monoclonal and bispecific antibodies development. |  Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. |  Marker Therapeutics Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. |  Celling Biosciences Celling Biosciences is a company developing point-of-care systems, surgical techniques, and technology platforms that create the optimal environment for regenerative cell therapies. |  UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. | |
Founding Date | Founding Date 1983 | Founding Date 2003 | Founding Date 2018 | Founding Date 2013 | Founding Date 1928 |
Type | Type Public | Type Public | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations Hampton, US HQ Fall River, US Needham, US New Haven, US | Locations Waltham, US HQ Lawrence, US | Locations Houston, US HQ | Locations Austin, US HQ Curitiba, BR Dubai, AE | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more |
Employees | Employees 1608% increase | Employees 35037% increase | Employees 888% decrease | Employees 47 | Employees 9,052 |
Valuation ($) | Valuation ($) 1.9 b | Valuation ($) 2.2 b | Valuation ($) 36.5 m | Valuation ($) N/A | Valuation ($) 34.3 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $1.5m (FY, 2025) | Revenue (est.) $163.4m (FY, 2023) | Revenue (est.) $3.5m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) €7.4b (FY, 2025) |
Cost of goods | Cost of goods $200k (FY, 2025) | Cost of goods $3.7m (FY, 2023) | Cost of goods N/A | Cost of goods N/A | Cost of goods €1.4b (FY, 2025) |
Gross profit | Gross profit $1.3m (FY, 2025) | Gross profit $159.6m (FY, 2023) | Gross profit N/A | Gross profit N/A | Gross profit €7.2b (FY, 2025) |
Net income | Net income ($258.8m) (FY, 2025) | Net income ($194.9m) (FY, 2023) | Net income ($12.2m) (FY, 2025) | Net income N/A | Net income €1.6b (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 2m | Total funding raised $ 714m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Deciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
View companyMarker Therapeutics
HQ
Houston, US
Employees
8
Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection.
View companyCelling Biosciences
HQ
Austin, US
Employees
47
Celling Biosciences is a company developing point-of-care systems, surgical techniques, and technology platforms that create the optimal environment for regenerative cell therapies.
View companyUCB
HQ
Brussels, BE
Employees
9,052
UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View company